Esmolol HCl

Catalog No.S4100 Batch:S410001

Print

Technical Data

Formula

C16H25NO4.HCl
Molecular Weight 331.83 CAS No. 81161-17-3
Solubility (25°C)* In vitro DMSO 66 mg/mL (198.89 mM)
Water 66 mg/mL (198.89 mM)
Ethanol 66 mg/mL (198.89 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Esmolol (ASL8052) is a cardioselective b-blocker, used to control rapid heartbeats or abnormal heart rhythms.
Targets
beta-adrenergic receptor [1]
In vitro Esmolol contains one asymmetric centre and exists as an enantiomeric pair, the (-)-enantiomer is active and the (+)-enantiomer is inactive, which is analogous to other P-blockers that have an oxypropranolamine nucleus. Esmolol has a rapid onset and offset of activity, the primary site of activity of Esmolol is on sinus node and atrioventricular (AV) nodal conduction systems. [1]
In vivo Esmolol (20 mg/kg) infusion in sepsis improves oxygen utilization of myocardium and preserves myocardial function in septic rats. [2] Esmolol (5 mg/kg, i.v.) produces a dose-dependent decrease in heart rate (HR) in rabbits, with the maximum percent reductions of 13%. Esmolol (5 mg/kg, i.v.) produces a dose-dependent decrease in mean arterial pressure (MAP) in rabbits, with the maximum percent reductions of 38.2%. [3] Esmolol (300 mg/kg) significantly decreases the heart rate, rate-pressure product, left ventricular contraction, cardiac output, and relative refractory period of the right ventricle, suppresses the AV nodal conduction, and increases the effective refractory period of the right ventricle and the preload of the left ventricle in canine. Esmolol (300 mg/kg) significantly reduces the isoproterenol-induced increase in heart rate and ventricular contraction in canine. [4]
Features The suppressive effects of ONO-1101 on cardiovascular performance are less than those of Esmolol at equipotent beta-blocking doses.

Protocol (from reference)

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.